慢性心不全における高感度トロポニンTの予後値:個々の患者のデータメタ解析
Alberto Aimo1, James L Januzzi2, Giuseppe Vergaro1,3
1Scuola Superiore Sant'Anna, Pisa, Italy (A.A., G.V., C.P., M.E.).
Circulation
|January 17, 2018
まとめ
高感度トロポニンTアッセイは,ほとんどの慢性心不全患者でトロポニンを検出します. このバイオマーカーは死亡率と入院率の強い予測因子であり,心臓機能不全の管理においてリスクの階層化を改善します.
科学分野:
- 心臓病科
- バイオマーカー
- 臨床試験
背景:
- 慢性心不全 (CHF) の患者は,しばしば高感度アッセイで検出可能なトロポニンレベルを示します.
- CHFにおけるこれらのトロポニン濃度の予後的意義については,さらなる解明が必要である.
研究 の 目的:
- 慢性心不全患者のリスク層分化の高感度トロポニンアッセイの有用性を評価する.
- CHFにおけるトロポニン濃度の予後的関連性を評価するためのメタ分析を行う.
主な方法:
- Medline,EMBASE,Cochrane Library,およびScopusで包括的な文献検索が行われました.
- 臨床的に安定した心不全患者の高感度トロポニンアッセイを用いた研究が含まれています.
- エンドポイントは,全原因による死亡,心血管疾患による死亡,心血管疾患による入院でした.
主要な成果:
- 9289人の患者を対象に10件の試験を分析し,全ての患者に対して高感度トロポニンTのデータがあった.
- 高感度トロポニンTは独立して全因死亡率,心血管死亡率,心血管入院率を予測した (HRは1. 40~1. 48,P<0. 001).
- トロポニンTを既存のリスクモデルに追加することで,様々な患者のサブグループにおけるリスク予測が著しく改善されました.
結論:
- 高感度トロポニンTは慢性心不全における有害な結果の堅実で独立した予測因子です.
- このバイオマーカーは,心不全患者の予後分層能力を強化します.
- トロポニンTの使用は,CHF患者の管理に役立つ追加のツールです.
関連する概念動画
01:29Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
01:17Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
01:27Heart Failure I: Introduction
966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
01:22Heart Failure VI: Adjunct Therapies
402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
01:22Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
01:30Heart Failure V: Medical Management
369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369